Triplet therapy for prostate cancer
- PMID: 35405082
- DOI: 10.1016/S0140-6736(22)00427-5
Triplet therapy for prostate cancer
Conflict of interest statement
I am the unremunerated chair of the ANZUP Cancer Trials Group and global co-chair of the ENZAMET trial and an unremunerated member or chair of industry advisory boards for Astellas, AstraZeneca, Bayer, Eisai, Ipsen, Janssen, Merck/Pfizer, Merck Sharp & Dohme, and Roche; all honoraria are invoiced by and paid directly to the ANZUP Cancer Trials Group.
Comment on
-
Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design.Lancet. 2022 Apr 30;399(10336):1695-1707. doi: 10.1016/S0140-6736(22)00367-1. Epub 2022 Apr 8. Lancet. 2022. PMID: 35405085 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
